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Abstract
Bone morphogenetic proteins (BMPs) are cytokines with strong ability to promote new bone
formation. Herein, we report the use of silk fibroin microparticles as carriers for the delivery
of BMP-2, BMP-9 or BMP-14. BMP-containing fibroin microparticles were prepared by a mild
methodology using dropwise addition of ethanol, exhibiting mean diameters of 2.7± 0.3 µm.
Encapsulation efficiencies varied between 67.9± 6.1 % and 97.7± 2.0 % depending on the type
and the amount of BMP loaded. Release kinetics showed that BMP-2, BMP-9 and BMP-14 were
released in two phases profile, with a burst release in the first two days followed by a slower
release, for a period of 14 days. The release data were best explained by Korsmeyer’s model and
the Fickian model of drug diffusion. Silk fibroin microparticles can offer a promising approach for
the sustained delivery of different BMPs in tissue engineering applications. Copyright  2010 John
Wiley & Sons, Ltd.
Received 20 June 2009; Accepted 11 November 2009
Keywords bone morphogenetic protein; silk fibroin; microparticles; drug delivery; BMP-2; BMP-9;
BMP-14
1. Introduction
Bone morphogenetic proteins (BMPs) have recently
sparked great interest in the tissue engineering field
due to their strong ability to promote new bone and
cartilage formation (Reddi, 2005; Bessa et al., 2008a).
Different materials have been proposed as carriers for
BMPs (Bessa et al., 2008b). Carriers are used to increase
the lifetime, stability and bioactivity of the BMPs and
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release these growth factors in both timely and site-
specific sustained ways. Microparticles as carriers can
offer the advantages of a controlled release, protecting
the protein from loss of bioactivity and targeting the
delivery into the specific injury site, with no dispersion
into surrounding tissues.
Several different microparticulated systems have been
investigated for the delivery of BMPs, most based
on polylactic-co-glycolic acid (PLGA) (Lee et al., 1994;
Phillips et al., 2006; Wei et al., 2007), on collagen (Wang
et al., 2003, Itoh et al., 2004) or on dextran (Chen et al.,
2006, 2007). Silk is an attractive choice as a material
for bone tissue engineering, due to being biocompatible,
slowly biodegradable and possessing excellent mechanical
properties such as tensile strength and rigidity which are
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highly desirable for a potential use as a scaffold for bone
tissue engineering (Scheibel 2006). Silk fibroin has been
investigated as a carrier for BMPs in several contributions
by Kaplan and colleagues, in form of membranes for
healing cranial defects in mice (Karageorgiou et al.,
2004), electrospun nanofibers (Li et al., 2006), and
scaffolds used for critical size defects in rats (Kirker-Head
et al., 2007) and mice (Karageorgiou et al., 2006).
Fibroin has been recently described to produce
microparticles when precipitated with ethanol at specific
fibroin concentrations and freeze temperature (Nam
and Park, 2001; Cao et al., 2007; Zhang et al., 2007).
Ethanol causes a shift in the random coil structure
of fibroin to an insoluble beta-sheet configuration
(Nam and Park, 2001). The addition of ethanol to
the fibroin solution causes it to either precipitate
to form a gel that can be used as a scaffold for
tissue engineering (Nazarov et al., 2004; Tamada, 2005)
or to form a gel consisting of micrometric particles
(Nam and Park, 2001; Zhang et al., 2007). If these
variables are controlled, a control of particle size
is possible and could be adapted to specific clinical
applications. Therefore, we were interested in using
this system as a possible delivery micro-carrier for
BMPs.
This study explores the use of silk fibroin microparticles
as a potential delivery system for the release of different
BMPs. Fibroin microparticles were produced under very
mild conditions, with a concomitant loading of BMP-
2, BMP-9 or BMP-14. Besides the fact that BMP-2 has
been widely researched as a osteogenic factor (Bessa
et al., 2008b), we also evaluated the potential of the
fibroin particles to deliver BMP-9 and BMP-14 due to
their potential in novel therapeutical applications. BMP-9
is reported to be one of the most osteogenic BMPs (Kang
et al., 2004) and BMP-14 is used in tendon and ligament
regeneration (Nakamura et al., 2003; Dines et al., 2007),
in spinal fusion (Spiro et al., 2001), bone formation
(Simank et al., 2004; Kadamatsu et al., 2008) and is
critical for digit and limb development (Merino et al.,
1999). The particles were characterized for morphology,
size distribution, water uptake, encapsulation efficiency
and the release kinetics of the three BMPs, with different
amounts of loaded growth factor.
2. Materials and methods
2.1. Materials
Silk containing Bombyx mori cocoons were purchased
from Halcyon Yarn, US. Human BMP-2, expressed in
Chinese Hamster Ovary (CHO) cells, was purchased from
Wyeth, UK. Human BMP-9 and BMP-14 were cloned
and expressed in Escherichia coli, purified by histidine-tag
affinity chromatography and freeze-dried, as described
elsewhere (Bessa et al., 2009). All chemicals were of
analytical grade and used as received.
2.2. Methods
2.2.1. Preparation of BMP silk fibroin
microparticles
Isolation of silk fibroin from Bombyx mori cocoons. Silk
fibroin was isolated from Bombyx mori cocoons following
a degumming protocol with modifications (Zhang et al.,
2007). Briefly, the cocoon shells of silkworm Bombyx
mori were degummed twice in a boiling solution of 0.5%
Na2CO3 for 0.5 h, at 90 ◦C, and the resulting degummed
fibers were subsequently dissolved, in a ternary system,
i.e. a mixed solution of calcium chloride, ethanol and
water (CaCl2/C2H5OH/H2O: 1 : 2 : 8 mole ratio) at 90 ◦C
for 6 h. The solution was then filtered (0.22 µm, Rotilab,
Germany), and the solution was extensively dialyzed,
using a cellulose semi-permeable (molecular weight cut-
off = 12000 kDa) membrane, against distilled water to
remove CaCl2, smaller molecules and impurities. The
fibroin was lyophilized and used for the preparation of
microparticles.
Microparticle preparation. Silk fibroin microparticles
were prepared by ethanol precipitation according to
the method described by Cao et al. (2007), with
modifications. A solution of 1% (w/v) silk fibroin in
phosphate buffer saline (PBS, pH 7.4) was prepared
(5 ml) and filtered with a 0.22 µm PVDF membrane
(Rotilab, Germany). For preparation of BMP loaded
particles, 5 or 50 µg/ml of growth factor (either BMP-2,
BMP-9 or BMP-14) were added to the fibroin suspension,
corresponding to a smaller or a larger dose of loaded
BMP (0.5 or 5 µg of BMP per mg of fibroin, respectively).
The solution was incubated at room temperature with
stirring (600 rpm) for 20 min. Absolute ethanol was
added dropwise to a ratio of 1 : 2 to the initial volume
of silk fibroin, and the solution incubated overnight at
−20 ◦C. Different ratios (ethanol to initial volume of
fibroin suspension) were also tested to investigate the
change in particle size. The resulting microparticles were
collected by centrifugation at 4000 g, 4 ◦C, for 5 min,
washed twice with distilled water and lyophilized, after
snap-freezing in liquid nitrogen, in a Christ Alpha 1–4
(Linder, Austria) lyophilizer. Sterile conditions were used
during the entire procedure.
2.2.2. Physical characterization
Scanning electron microscopy (SEM). Fibroin particles
were morphologically characterized by scanning electron
microscopy (SEM). SEM analysis was performed on
gold-coated air-dried samples (Agar Sputercoater 108,
Essex, UK) and using a Philips XL20 microscope (Philips,
Eidhoven, The Netherlands). Particle size measurements
were obtained from different micrographs acquired in
the SEM.
Size distribution. Measurements of particle size were
performed on freshly prepared samples by dynamic light
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scattering (DLS), using a Zetasizer NanoZS (Malvern,
UK). For the analysis, each sample was diluted to an
appropriate concentration with ultrapure (filtered) water.
Each analysis lasted 60 s and was performed at 25 ◦C.
Water uptake and degradation studies. The hydration
degree of unloaded fibroin microparticles was evaluated
after immersion into PBS, at 37 ◦C, for periods up to
30 days (30 min, 4 h, 24 h, 2 d, 5 d, 8 d, 14 d, 21 d and
E.E.(%) = Total BMP amount(µg)− Free BMP amount(µg)
Total BMP amount
× 100
L.C.(µg BMP/mg particles) = Total BMP amount(µg)− Free BMP amount(µg)
Microparticles weight(mg)
30 d). The weight loss of unloaded fibroin particles was
assessed after immersion into PBS, at 37 ◦C, for periods
up to 30 days (1 d, 2 d, 5 d, 8 d, 14 d and 30 d). All
experiments were performed in triplicate. Percentage of
water uptake (WU) after each time period of immersion
(t) was calculated using the following equation:
WU (%) = (Ww −Wj)
Wi
× 100
The percentage of mass remaining (MR) after each time
period (t) was calculated using the following equation:
WL(%) = Wd
Wi
× 100
‘Ww’ and ‘Wd’ correspond, respectively, to the weight of
fibroin particles in wet state (after removal from solution,
washing with distilled water and soft-blotting with filter
paper) and dry state (after removal of solution, washing
after distilled water and freeze-drying); ‘Wi’ correspond
to the initial dry weight of particles, before immersion.
2.2.3. In vitro drug release studies
Quantification of protein. For measurement of BMP-
2 concentration, a BMP-2 sandwich-type ELISA kit
(Eubio, Austria) was used, following the manufacturer’s
instructions. A calibration curve was obtained using
standard preparations of BMP-2 of known concentration.
For detection of BMP-9 and BMP-14, the sample
concentrations were estimated by dot blot with the
use of an anti-histidine tag antibody (Sigma, US). The
blot intensities were compared with standards of known
concentration, using image analysis (ChemiImage 4400,
Alpha Innotech, US).
Determination of loading capacity and encapsulation effi-
ciency. The microparticle encapsulation efficiency was
determined upon their separation from the aqueous
preparation medium containing the non-associated pro-
tein (free BMP) by centrifugation (10 000 g, 10 min). The-
oretical drug content (total BMP)was calculated assuming
that the entire amount of drug added to the fibroin solu-
tion was encapsulated and no drug loss occurred at any
stage of the particle preparation. All experiments were
performed in triplicate. The microparticle encapsulation
efficiency (E.E.) and BMP loading capacity (L.C) were
calculated using the following equations:
In vitro release. Silk fibroin particles loaded with BMP-2,
BMP-9 or BMP-14 (initial loading of 0.5 or 5 µg/mg) were
suspensed in 5 ml PBS (pH 7.4), at 37 ◦C, with 200 rpm
agitation, to a concentration of 2 mg/ml of microparticles.
At pre-determined time points (1 h, 4 h, 1 d, 2 d, 4 d, 8
d and 14 d), 250 µl of solution was removed, centrifuged
(10 000 g, 10 min) and filtered in 0.22 µm membranes
and stored at −20 ◦C until quantification. The volume of
solution removed was replaced with fresh buffer. Sterile
conditions were applied to prevent any contamination of
samples. All experiments were performed in triplicate.
Percentage of release was obtained by comparing the
measured growth factor content with the actual loading
capacity.
Release kinetics models. To study the release kinetics,
the data obtained from the in vitro release was treated
accordingly to zero order as cumulative amount of
drug released vs. time (equation 1), first order as log
cumulative percent drug remaining vs. time (equation 2),
Higuchi kinetics as cumulative percent drug released
vs. square root of time (equation 3) and Korsmeyer
kinetics as log cumulative percent drug released vs.
log time (equation 4) (Huguchi, 1963; Chowdary and
Ramesh, 1993; Hadjiioannou et al., 1993; Bourne,
2002):
R = k1t (1)
Log UR = k2t 2.303 (2)
R = k3t 0.5 (3)
Log R = log k4 + n log t (4)
where R and UR are released and unreleased percentages,
respectively, at time (t); k1, k2, k3 and k4 are the
rate constants of zero-order, first order, Higuchi and
Korsmeyer models, respectively; n is a exponent that
characterizes the mechanism of release.
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2.2.4. Statistical analysis
Experiments were performed in triplicate (n = 3) and
mean ± standard deviations were reported. Student’s
t test was used for statistical analysis using a two-tailed
paired test. Statistical significance was defined as p < 0.01
for a 99% confidence.
3. Results
3.1. Morphology, size distribution
and encapsulation efficiency
The morphology of fibroin particles observed by
SEM is shown in Figure 1. Fibroin formed spherical
microparticles with diameters increasing when the ratio
of ethanol to silk solution (used during the prepara-
tion of particles) increased. The particles had mean sizes
of 580.0± 120.6 nm using a 1 : 2 ratio of ethanol and
silk, increasing up to 1.1± 0.3 µm with a 1 : 3 ratio
(p < 0.01), and to 1.2± 0.4 µm with 1 : 4 ratio (not sig-
nificant). Using size distribution, the particles, using a
1 : 2 ratio, showed an average size of 2.7± 0.3 µm, in
wet state (Figure 2). The largest part of microspheres
(88.5%) had sizes ranging from 1.5 to 3.0 µm in diam-
eter. The encapsulation efficiency of BMP-2 into the
fibroin particles was 97.7± 2.0 % per total amount of
growth factor added during the preparation of the par-
ticles, when 0.5 µg BMP-2 (per mg fibroin) was loaded,
and 76.8± 3.5 %, when 5.0 µg of BMP-2 were loaded
(Table 1). The loading capacity was 0.69± 0.06 µg of
BMP-2 per mg of fibroin particles, and 5.4± 0.5 µg of
BMP-2 per mg of particles, when the different amounts
were loaded. For BMP-9, the encapsulation efficiency was
90.2± 5.9 % and 72.4± 4.4 %, and the loading capac-
ity was 0.63± 0.17 and 5.1± 0.5 µg/mg of particles,
when 0.5 or 5.0 µg BMP-9 were loaded, respectively.
For BMP-14, the encapsulation efficiency was 82.5± 6.0
% and 67.9± 6.1 %, and the loading capacity was
0.60± 0.17 and 4.8± 0.6 µg of BMP-14 per mg of par-
ticle weight, when 0.5 or 5.0 µg BMP-14 were loaded,
respectively.
3.2. Water uptake and degradation studies
The swelling occurred rapidly during the first two days
of immersion, up to 48.5± 6.7 % after 30 min and up
to 167.7± 14.1 % after day 2 (p < 0.01), with water
uptake reaching a peak at day 8 with 227.7± 26.6 %
(p < 0.01) (Figure 3). This was followed by a slow and
gradual decline in wet weight, with a swelling value of
203.4± 25.0 % (non-significant) after day 30, possibly
due to weight loss. The remaining mass was 97.1± 1.5 %
after day 5, 95.4± 2.5 % after day 14, and 93.5± 3.3 %
after day 30 (Figure 4).
3.3. In vitro release studies
Drug release studies were evaluated when fibroin particles
loaded with BMP-2, BMP-9 and BMP-14 were immersed
in PBS, at 37 ◦C, with agitation. The microparticles loaded
with 0.5 µg of BMPs/mg fibroin, showed an initial burst
release with more than half of protein being released
during the first two days (64.1± 5.1 % for BMP-2,
78.4± 7.9 % for BMP-9 and 62.5± 7.3 % for BMP-14),
Figure 1. SEM micrographs of unloaded fibroin microparticles,
produced with different ethanol : silk solution ratios: A) 1 : 2
ratio, B) 1 : 3 ratio, and C) 1 : 4 ratio. Magnification 10.000 x.
Scale 5 µm
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Figure 2. Size distribution of unloaded silk fibroin particles.
Almost all particles showed sizes ranging between 2 and 3 µm,
with a mean diameter of 2.7± 0.3 µm. Size refers to particle
diameter (nanometers)
Table 1. Loading and encapsulation efficiencies of BMP-loaded
fibroin microparticles (mean ± SD, n = 3)
Growth
factor
Amount of growth
factor/mg fibroin,
prior to
loading (µg)
Encapsulation
efficiency (%)
Loading
capacity (µg
BMP/mg
particles)
BMP-2 0.5 97.7± 2.0 0.69± 0.06
BMP-9 0.5 90.2± 5.9 0.63± 0.17
BMP-14 0.5 85.8± 6.0 0.60± 0.17
BMP-2 5.0 76.8± 3.5 5.4± 0.5
BMP-9 5.0 72.4± 4.4 5.1± 0.5
BMP-14 5.0 67.9± 6.1 4.8± 0.6
Encapsulation efficiency (%) = {[total BMP amount (µg) –free BMP
(µg)]/total BMP (µg)}× 100. Loading capacity (µg BMP/mg particles) =
{[total BMP amount (µg) –free BMP (µg)]/microparticles weight (mg)}.
Figure 3. Evolution of water uptake behavior of unloaded silk
fibroin microparticles in phosphate buffer saline as a function of
immersion time (t). (mean± SD, n = 3). Water uptake increased
significantly up to 5 days, peaked after 8 days, and then slightly
declined (non-significantly). * p < 0.01 related to the difference
between consecutive time measurements
followed by a second phase of a slower and more
sustained release with 90.1± 6.9 % of BMP-2, 90.9± 5.2
% of BMP-9, and 80.4± 5.6% of BMP-14, released after
14 days (Figure 5A). This corresponds to a release rate,
of 15 ng/day, 7 ng/day and 8 ng/day (per mg of fibroin),
between day 2 and 14, for each BMP, after a burst release
of 442 ng, 499 ng and 377 ng of each BMP (in 2 days).
The particles loaded with 5 µg/mg of BMPs showed an
initial release of about 28.6± 5.5 % of BMP-2, 22.7± 6.3
% of BMP-9 and 14.1± 6.7 % of BMP-14 being released
after two days (Figure 5B), which corresponds to 1.5 µg,
1.1 µg and 0.7 µg of each growth factor. After 14 days,
Figure 4. Evolution of weight loss of unloaded fibroin particles
in phosphate buffer saline as a function of immersion time (t).
(mean± SD, n= 3). The remaining mass decreased to 97.1± 1.5
% after day 5, 95.4± 2.5 % after day 14, and 93.5± 3.3 % after
day 30
Figure 5. Release kinetics of BMP-2, BMP-9 and BMP-14
immobilized in fibroin particles. ELISA was used for BMP-2
quantification and dot-blot for BMP-9 and BMP-14 quantification
(Mean ± SD, n = 3). A) Release from particles containing 0.5 µg
of BMP per mg of fibroin; B) release from particles containing
5.0 µg of BMP per mg of fibroin. Cumulative release is expressed
in percentage of loaded protein
47.3± 7.0 % BMP-2, 38.9± 8.9 % BMP-9, and 33.2± 8.8
% BMP-14 were released, corresponding to a release rate
of 86 ng/day, 72 ng/day and 76 ng/day, for each BMP.
At the end of this period, 2.5 µg, 2.0 µg and 1.5 µg of
each growth factor were (cumulatively) released from the
particles (per mg of fibroin).
The release data of the BMPs were treated accordingly
to first order, Higuchi and Korsmeyer equations (Table 2)
and zero order equation (data not shown). The release
data of BMP-2, BMP-9 and BMP-14 were best explained by
Korsmeyer’s equation (r2 varying between 0.92 and 0.98),
followed by Higuchi’s equation (r2 varying between 0.75
and 0.95) and by first order kinetics (r2 varying between
0.71 and 0.91). The release exponent ‘‘n’’ of Korsmeyer’s
model, varied in the different experimental conditions
between 0.30 and 0.42. Since n<0.43 the release data
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Table 2. Release kinetics of BMPs immobilized in fibroin particles
Growth
factor
Amount of
growth factor/
mg fibroin, prior
to loading (µg)
Equation
modelling
BMP-2 0.5 y = – 0.057x+ 1.7547; r2 = 0.91a
y = 17.926x+ 26.183; r2 = 0.85b
y = 0.3029x+ 1.6459; r2 = 0.97,n = 0.30c
BMP-9 0.5 y = – 14.148x+ 25.648; r2 = 0.71a
y = 19.509x+ 25.325; r2 = 0.75b
y = 0.3674x+ 1.6277; r2 = 0.92,n = 0.37c
BMP-14 0.5 y = – 0.0344x+ 1.8002; r2 = 0.70a
y = 18.232x+ 17.785; r2 = 0.80b
y = 0.4195x+ 1.519; r2 = 0.92, n = 0.42c
BMP-2 5.0 y = – 0.0133x+ 1.9131; r2 = 0.71a
y = 11.018x+ 8.4402; r2 = 0.88b
y = 0.385x+ 1.2845; r2 = 0.98, n = 0.39c
BMP-9 5.0 y = – 77.226x+ 150.34; r2 = 0.77a
y = 8.5682x+ 7.496; r2 = 0.92b
y = 0.301x+ 1.2361; r2 = 0.96, n = 0.30c
BMP-14 5.0 y = – 0.0083x+ 1.9499; r2 = 0.83a
y = 7.2919x+ 5.3548; r2 = 0.95b
y = 0.2978x+ 1.1429; r2 = 0.97,n = 0.30c
aFirst order (log cumulative percentage drug remaining vs. time).
bHigushi kinetics (cumulative percentage drug released vs. square root of
time).
cKorsmeyer kinetics (log cumulative percentage drug released vs. log
time), with correlation values (r2).
fitted a Fickian mode of diffusion (Ritger and Peppas,
1987). The zero order modeling showed low linearity
(data not shown).
4. Discussion
Microparticles as drug carriers have the advantages of
sustained or controlled release, the possibility of drug
targeting to specific tissues, thus reducing side effects
of drugs and improving their bioavailability. Therefore,
microparticles as delivery systems have drawn much
attention in the pharmaceutical field and have been
successfully applied in several clinical trials. The goal
of this study was to assess the possibility of the use of silk-
derived fibroin as a microparticle carrier for the release of
different BMPs.
Fibroin microspheres were manufactured in a semi-
aqueous system, avoiding the use of toxic organic solvents,
harsh conditions, cross-linking agents or surfactants, as
a way of minimizing the risk of a loss of BMP activity
during the particle preparation. The group of Kaplan and
colleagues have recently reported that fibroin could form
either particles or films with methanol and conserving
the activity of incorporated drugs (Hofmann et al., 2006;
Wang et al., 2007). When compared with other methods
of processing, such as spray drying (Hino et al., 2003),
this approach not only avoids conditions unfavorable for
the growth factor activity such as high temperature, but
it also allows generating particles with smaller size.
The microparticles were easily prepared under sterile
conditions and had a small size in a rather narrow size
distribution. The size of particles was significantly smaller
in the SEM counterpart images, probably due to the
large swelling of the particles in the wet state. This was
reported also in a former work (Cao et al., 2007). The
small particle size presented a double advantage, first by
potentially enhancing the drug availability in the particle
surface, and also by providing a surgical material that may
be suitable for injectable implantation in bone defects in
a slurry form. The BMPs were successfully encapsulated
with a rather high efficiency, which is comparable to
other works (Patel et al., 2008; Wenk et al., 2008). The
lower encapsulation efficiencies observed for BMP-14
could be due to the differences in the BMP charge and
its interaction with the fibroin material. Interestingly,
this BMP has a lower isoelectric point when compared to
BMP-2 (calculated using Expasy Proteomics tool Compute
pI/Mw, at www.expasy.org; pI = 6.3 for BMP-2, pI = 5.9
for BMP-9 and pI = 5.8 for BMP-14). It is possible that
this growth factor interacted to a weaker extent with the
fibroin carrier since fibroin has an acidic isoelectric point
(pI = 5.5).
During the initial stages of swelling, the fibroin
microspheres showed substantial water uptake, mostly
during the first two days of immersion, which also
corresponded to the initial burst release, as the drug
was rapidly released from the particles. Then, as swelling
became gradually counterbalanced, the BMP was released
slower and the release was mainly determined by the
diffusion of the growth factor from the particle to the
medium. It is possible that the erosion of the carrier
contributed little to this, since we have found both that the
release data best fittedwith the Korsmeyer’s equations and
slope values between 0.30 and 0.42, thus indicating that
the release was of a Fickian type of diffusion, controlled
by only one mechanism and thus not dependent on carrier
erosion (this applies when n<0.43, in the case of spherical
particles) (Ritger and Peppas, 1987). In fact, as we have
observed the silk fibroin microparticles exhibited a slow
rate of degradation. The release amounts during this
phase were such that they could meet the concentrations
of growth factor required in most in vitro and in vivo
applications (in the range of few hundreds of nanograms
to a few micrograms), by choosing a specific amount
of BMP during the loading process (Kenley et al., 1994;
Hosseinkhani et al., 2007; Wei et al., 2007; Bessa et al.,
2009).
The silk fibroin microspheres have shown to work as
a microcarrier that provides a sustained release of the
different BMPs in a timewise manner that could be used
in bone regenerative applications. The bioactivity of the
BMPs released from the silk fibroin microparticles will be
explored in future works.
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